NASH drugs race to cross the finish line
After the FDA rejected Intercept’s Ocaliva NDA, multiple companies are taking aim at becoming the first US-approved NASH therapy.
PCM Trials WP
FDA extends review of GSK’s myelofibrosis drug
FDA grants orphan drug designation to DTx Pharma’s CMT1A therapeutic
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Thermo Fisher Scientific opens sterile drug facility in Singapore
Sanofi and AstraZeneca’s RSV antibody shows mettle in real-world results
Recursion plans $87.5m acquisitions to shore up AI drug discovery
